Daclizumab Subcutaneous and Emend (Aprepitant Oral Suspension)
Determining the interaction of Daclizumab Subcutaneous and Emend (Aprepitant Oral Suspension) and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: daclizumab
Brand name: Zinbryta, Zenapax
Synonyms: Daclizumab
Generic Name: aprepitant
Brand name: Emend, Cinvanti, Emend 3-Day, Emend 2-Day
Synonyms: Emend
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Daclizumab Subcutaneous-Emend (Fosaprepitant)
- Daclizumab Subcutaneous-Emend for Injection
- Daclizumab Subcutaneous-Emend Intravenous
- Daclizumab Subcutaneous-Emflaza
- Daclizumab Subcutaneous-Emflaza (Deflazacort Oral Suspension)
- Daclizumab Subcutaneous-Emflaza (Deflazacort Tablets)
- Emend (Aprepitant Oral Suspension)-Dacogen
- Emend (Aprepitant Oral Suspension)-Dacomitinib
- Emend (Aprepitant Oral Suspension)-Dactinomycin
- Emend (Aprepitant Oral Suspension)-Dactinomycin Injection
- Emend (Aprepitant Oral Suspension)-Dactinomycin Intravenous
- Emend (Aprepitant Oral Suspension)-Daklinza